Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR modulators for those with CF mutations or IgG supplementation.
Clinical Brief: Etiologic Evaluation and First-Line Treatment of Bronchiectasis
Main Discussion Topics
Key Points for Physicians
Notable Insights
In approximately 40% to 50% of cases, etiologic evaluation can identify host susceptibility factors that allow for targeted interventions beyond general management.
Clinical Significance
Combining universal bronchiectasis management approaches with etiology-specific interventions creates a more effective personalized treatment strategy.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More